GUTS
Fractyl Health, Inc.
An American medical company treating obesity and type 2 diabetes at their root. Its lead procedure, Revita, uses a heat-based endoscopic device to resurface the lining of the small intestine, helping people keep weight off after stopping GLP-1 drugs; its Rejuva platform delivers genes that reprogram insulin-making pancreatic cells. Founded in 2010 as MedCatalyst, the firm took its name from "fractal," echoing the repeating folds inside the intestine, and trades on Nasdaq as "GUTS."
CUSIP: 35168W103HealthcareUS1 holder
Total Value
$3.16M
Total Shares
3.97M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
